Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PFIZER's DIFLUCAN (FLUCONAZOLE) ORAL SUSPENSION DOSAGE FORM IS "APPROVABLE"

Executive Summary

Pfizer's NDA for an oral suspension form of the broad spectrum antifungal Diflucan (fluconazole) has been "approvable" at FDA since April 19. Diflucan suspension (NDA 20-090) is approvable for 10 mg/ml and 40 mg/ml doses. The once-a-day antifungal is currently marketed in tablet and I.V. forms for the treatment of cryptococcal meningitis and candidiasis -- fungal infections that frequently afflict AIDS patients. Diflucan was approved in the tablet and I.V. forms on Jan. 29, 1990 with a "1AA" rating from FDA. Including its first year of marketing in the U.S., the antifungal generated worldwide sales of $ 234 mil. in 1990. Pfizer shareholders were told at the April 25 annual meeting that the company also intends to file a supplemental NDA this year for the prophylactic use of Diflucan in systemic fungal infections. The company also has said it will seek a pediatric indication for the drug.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel